Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target lowered by Canaccord Genuity Group from $91.00 to $90.00 in a report issued on Monday morning, Marketbeat reports. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

ANIP has been the topic of a number of other reports. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Guggenheim restated a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $75.11 on Monday. The business has a 50-day moving average of $81.00 and a 200-day moving average of $79.11. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 16.19 and a beta of 0.44. ANI Pharmaceuticals has a 1 year low of $70.15 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm’s revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 3,313 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the sale, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares of the company’s stock, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,487 shares of company stock valued at $1,508,665 over the last 90 days. 8.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors have recently made changes to their positions in ANIP. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. raised its stake in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares during the period. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals in the fourth quarter worth approximately $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals in the second quarter worth approximately $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.